PTC Therapeutics Wins $211M Bankruptcy Auction for Sangamo’s Fabry Disease Gene Therapy
PTC Therapeutics has agreed to pay $111 million upfront, plus up to $100 million in regulatory milestones, to acquire ST-920 (isaralgagene civaparvovec), a BLA-stage one-time AAV gene therapy for Fabry disease, from bankrupt Sangamo…
